Literature DB >> 25904725

Brain Structure in Neuropsychologically Defined Subgroups of Schizophrenia and Psychotic Bipolar Disorder.

Neil D Woodward1, Stephan Heckers2.   

Abstract

BACKGROUND: Neuropsychological impairment is heterogeneous in psychosis. The association of intracranial volume (ICV) and total brain volume (TBV) with cognition suggests brain structure abnormalities in psychosis will covary with the severity of cognitive impairment. We tested the following hypotheses: (1) brain structure abnormalities will be more extensive in neuropsychologically impaired psychosis patients; (2) psychosis patients with premorbid cognitive limitations will show evidence of hypoplasia (ie, smaller ICV); and (3) psychosis patients with evidence of cognitive decline will demonstrate atrophy (ie, smaller TBV, but normal ICV).
METHODS: One hundred thirty-one individuals with psychosis and 97 healthy subjects underwent structural magnetic resonance imaging and neuropsychological testing. Patients were divided into neuropsychologically normal and impaired groups. Impaired patients were further subdivided into deteriorated and compromised groups if estimated premorbid intellect was average or below average, respectively. ICV and TBV were compared across groups. Localized brain volumes were qualitatively examined using voxel-based morphometry.
RESULTS: Compared to healthy subjects, neuropsychologically impaired patients exhibited smaller TBV, reduced grey matter volume in frontal, temporal, and subcortical brain regions, and widespread white matter volume loss. Neuropsychologically compromised patients had smaller ICV relative to healthy subjects, and neuropsychologically normal and deteriorated patient groups, but relatively normal TBV. Deteriorated patients exhibited smaller TBV compared to healthy subjects, but relatively normal ICV. Unexpectedly, TBV, adjusted for ICV, was reduced in neuropsychologically normal patients.
CONCLUSIONS: Patients with long-standing cognitive limitations exhibit evidence of early cerebral hypoplasia, whereas neuropsychologically normal and deteriorated patients show evidence of brain tissue loss consistent with progression or later cerebral dysmaturation.
© The Author 2015. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  brain volume; cognition; neurodevelopmental; neuroprogressive; psychosis

Mesh:

Year:  2015        PMID: 25904725      PMCID: PMC4601708          DOI: 10.1093/schbul/sbv048

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  57 in total

1.  Neuropsychological assessment of monozygotic twins discordant for schizophrenia.

Authors:  T E Goldberg; J D Ragland; E F Torrey; J M Gold; L B Bigelow; D R Weinberger
Journal:  Arch Gen Psychiatry       Date:  1990-11

2.  The positive and negative syndrome scale (PANSS) for schizophrenia.

Authors:  S R Kay; A Fiszbein; L A Opler
Journal:  Schizophr Bull       Date:  1987       Impact factor: 9.306

3.  Elaboration on premorbid intellectual performance in schizophrenia: premorbid intellectual decline and risk for schizophrenia.

Authors:  Abraham Reichenberg; Mark Weiser; Michael A Rapp; Jonathan Rabinowitz; Asaf Caspi; James Schmeidler; Haim Y Knobler; Gad Lubin; Daniela Nahon; Philip D Harvey; Michael Davidson
Journal:  Arch Gen Psychiatry       Date:  2005-12

4.  Dimensions of intelligence in schizophrenia: evidence from patients with preserved, deteriorated and compromised intellect.

Authors:  Johanna C Badcock; Milan Dragović; Flavie A V Waters; Assen Jablensky
Journal:  J Psychiatr Res       Date:  2005-01       Impact factor: 4.791

5.  No, it is not possible to be schizophrenic yet neuropsychologically normal.

Authors:  Christopher M Wilk; James M Gold; Robert P McMahon; Katherine Humber; Virginia N Iannone; Robert W Buchanan
Journal:  Neuropsychology       Date:  2005-11       Impact factor: 3.295

6.  Intellectual decline in schizophrenia: evidence from a prospective birth cohort 28 year follow-up study.

Authors:  Larry J Seidman; Stephen L Buka; Jill M Goldstein; Ming T Tsuang
Journal:  J Clin Exp Neuropsychol       Date:  2006-02       Impact factor: 2.475

7.  Cognitive development in schizophrenia: follow-back from the first episode.

Authors:  Robert M Bilder; Gail Reiter; Jay Bates; Todd Lencz; Philip Szeszko; Robert S Goldman; Delbert Robinson; Jeffrey A Lieberman; John M Kane
Journal:  J Clin Exp Neuropsychol       Date:  2006-02       Impact factor: 2.475

8.  Relationships between measures of brain functions and general intelligence.

Authors:  R M Reitan
Journal:  J Clin Psychol       Date:  1985-03

Review 9.  The infant skull: a vault of information.

Authors:  Ronald B J Glass; Sandra K Fernbach; Karen I Norton; Paul S Choi; Thomas P Naidich
Journal:  Radiographics       Date:  2004 Mar-Apr       Impact factor: 5.333

10.  Impact of intellectual status on response to cognitive task training in patients with schizophrenia.

Authors:  J M Fiszdon; J Choi; G J Bryson; M D Bell
Journal:  Schizophr Res       Date:  2006-06-05       Impact factor: 4.662

View more
  23 in total

1.  Childhood temperament is associated with distress, anxiety and reduced quality of life in schizophrenia spectrum disorders.

Authors:  Brandee Feola; Kristan Armstrong; Neil D Woodward; Stephan Heckers; Jennifer Urbano Blackford
Journal:  Psychiatry Res       Date:  2019-03-11       Impact factor: 3.222

2.  Neuropsychological functioning in early and chronic stages of schizophrenia and psychotic bipolar disorder.

Authors:  Margo W Menkes; Kristan Armstrong; Jennifer Urbano Blackford; Stephan Heckers; Neil D Woodward
Journal:  Schizophr Res       Date:  2018-10-26       Impact factor: 4.939

3.  Infusions of Nerve Growth Factor Into the Developing Frontal Cortex Leads to Deficits in Behavioral Flexibility and Increased Perseverance.

Authors:  Sagar J Desai; Brian L Allman; Nagalingam Rajakumar
Journal:  Schizophr Bull       Date:  2018-08-20       Impact factor: 9.306

4.  Microglial Pruning of Synapses in the Prefrontal Cortex During Adolescence.

Authors:  Allyson P Mallya; Hui-Dong Wang; Han Noo Ri Lee; Ariel Y Deutch
Journal:  Cereb Cortex       Date:  2019-04-01       Impact factor: 5.357

5.  Heterogeneity of Outcomes and Network Connectivity in Early-Stage Psychosis: A Longitudinal Study.

Authors:  Shi Yu Chan; Roscoe Brady; Melissa Hwang; Amy Higgins; Kathryn Nielsen; Dost Öngür; Mei-Hua Hall
Journal:  Schizophr Bull       Date:  2021-01-23       Impact factor: 9.306

6.  Functional connectivity in distinct cognitive subtypes in psychosis.

Authors:  Kathryn E Lewandowski; Julie M McCarthy; Dost Öngür; Lesley A Norris; Geoffrey Z Liu; Richard J Juelich; Justin T Baker
Journal:  Schizophr Res       Date:  2018-08-17       Impact factor: 4.939

7.  Deviation from expected cognitive ability across psychotic disorders.

Authors:  W C Hochberger; T Combs; J L Reilly; J R Bishop; R S E Keefe; B A Clementz; M S Keshavan; G D Pearlson; C A Tamminga; S K Hill; J A Sweeney
Journal:  Schizophr Res       Date:  2017-05-22       Impact factor: 4.939

8.  The Relationship of Intellectual Functioning and Cognitive Performance to Brain Structure in Schizophrenia.

Authors:  Letícia Sanguinetti Czepielewski; Lei Wang; Clarissa S Gama; Deanna M Barch
Journal:  Schizophr Bull       Date:  2017-03-01       Impact factor: 9.306

9.  Widespread Volumetric Reductions in Schizophrenia and Schizoaffective Patients Displaying Compromised Cognitive Abilities.

Authors:  Tamsyn E Van Rheenen; Vanessa Cropley; Andrew Zalesky; Chad Bousman; Ruth Wells; Jason Bruggemann; Suresh Sundram; Danielle Weinberg; Roshel K Lenroot; Avril Pereira; Cynthia Shannon Weickert; Thomas W Weickert; Christos Pantelis
Journal:  Schizophr Bull       Date:  2018-04-06       Impact factor: 9.306

10.  Mapping cognitive trajectories across the course of illness in psychosis.

Authors:  Kathryn E Lewandowski
Journal:  Schizophr Res       Date:  2018-12-27       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.